Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sebastien Balez"'
Autor:
V. Jarugula, Sebastien Balez, Yan-Ling He, S. Schwartz, Y. Wang, W.P. Dole, Denise Serra, J. Bullock, G.-J. Riviere, Monica Ligueros-Saylan
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 46:349-364
Background: Vildagliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4) that improves glycemic control and pancreatic β-cell function in patients with Type 2 diabetes. Vildagliptin may be an appropriate agent to combine with other antih
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0b49d69d7dcb2e69ff1ce1a827d7757
https://doi.org/10.5414/cpp46349
https://doi.org/10.5414/cpp46349
Autor:
Yan-Ling He, Aziz Laurent, Sebastien Balez, Ron Sabo, Brian M. Sadler, Joelle Campestrini, Dan Howard, Yibin Wang, Monica Ligueros-Saylan
Publikováno v:
Clinical Pharmacokinetics. 46:787-802
Vildagliptin is a potent, selective, orally active inhibitor of dipeptidylpeptidase-IV being developed for the treatment of type 2 diabetes mellitus. The objective of this study was to assess the absolute oral bioavailability of vildagliptin by compa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a45751830955feabf4e8e42157d7fb8c
https://doi.org/10.2165/00003088-200746090-00006
https://doi.org/10.2165/00003088-200746090-00006
Publikováno v:
International journal of clinical pharmacology and therapeutics. 47(5)
The International Conference on Harmonization (ICH) E14 guidance recommends that almost all drugs should undergo careful clinical testing in a thorough QT/QTc study. Deferasirox (Exjade, ICL670) is a once-daily oral iron chelator, developed for the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1647111ff4138c741f300982d47589a8
https://pubmed.ncbi.nlm.nih.gov/19473594
https://pubmed.ncbi.nlm.nih.gov/19473594
Publikováno v:
International journal of clinical pharmacology and therapeutics. 46(10)
Deferasirox (Exjade, ICL670) is a potent iron chelator, recently approved as first-line therapy for the treatment of blood-transfusion-related iron overload. Iron deposition in the heart may lead to cardiac dysfunction in patients with iron overload.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee97cc3caa7cfc4c56f11e1f584cd9b9
https://pubmed.ncbi.nlm.nih.gov/18826866
https://pubmed.ncbi.nlm.nih.gov/18826866
Publikováno v:
Journal of clinical pharmacology. 48(8)
Deferasirox is a novel iron chelator formulated as tablets for dispersion (suspension) for once-a-day oral administration. The current study evaluated the absolute bioavailability of a single 375-mg oral dose of deferasirox administered in the form o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15fc3bc71ae1cfb134f8c7c6e49a09e4
https://pubmed.ncbi.nlm.nih.gov/18508948
https://pubmed.ncbi.nlm.nih.gov/18508948
Autor:
Axel Krebs-Brown, Anne Gardin, Yannick Batard, Claire Souppart, Silke Appel-Dingemanse, Gerard Greig, Sebastien Balez
Publikováno v:
Journal of clinical pharmacology. 48(5)
Two studies characterized single- and multiple-dose pharmacokinetics of licarbazepine immediate-release tablets and food effects on single-dose pharmacokinetics. In 1 study, 12 volunteers received 500 mg licarbazepine on day 1, 500 mg bid on days 3 t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fb980125749e56995e3241500ef3ca7
https://pubmed.ncbi.nlm.nih.gov/18258749
https://pubmed.ncbi.nlm.nih.gov/18258749
Autor:
T Dumortier, S Morisson, Catherine Dutreix, Romain Sechaud, F Pommier, Sebastien Balez, E Brun
Publikováno v:
International journal of clinical pharmacology and therapeutics. 46(2)
Deferasirox (ExjadeA, ICL670) is a new, once-daily oral iron chelator, recently approved as first-line therapy in the treatment of iron overload resulting from blood transfusions. In registration studies, deferasirox tablets were dispersed in non-car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39e9e278c4db3cd9fe02c9ef37d2957
https://pubmed.ncbi.nlm.nih.gov/18218291
https://pubmed.ncbi.nlm.nih.gov/18218291
Autor:
Michael Merz, Silke Appel-Dingemanse, Francois Mercier, Sebastien Balez, Anni Agarwal, Claire Souppart
Publikováno v:
The FASEB Journal. 21
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4c5dc0b3e6d2659216f42c8c06212a0
https://doi.org/10.1096/fasebj.21.5.a417
https://doi.org/10.1096/fasebj.21.5.a417
Autor:
Gino Gerosa, Nizar Yonan, Romain Sechaud, Heather J. Ross, Leslie W. Miller, Ernst Ulrich Koelle, Manfred Hummel, Sebastien Balez
Publikováno v:
Clinical transplantation. 21(1)
Sequential pharmacokinetic assessments were performed at five centers within the context of a multicenter, single-blind, randomized clinical trial comparing the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) and mycophe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b2402cf27a1d035820b5b74b436d857
https://pubmed.ncbi.nlm.nih.gov/17302587
https://pubmed.ncbi.nlm.nih.gov/17302587
Autor:
Herwig Ulf Meier-Kriesche, Romain Sechaud, Franck Picard, Ching Ming Yeh, Paula Minnick, Robert Schmouder, Bruce Kaplan, Marie Claude Bastien, Sebastien Balez
Publikováno v:
Clinical transplantation. 19(4)
Enteric-coated mycophenolate sodium (EC-MPS) (myfortic) is an advanced formulation delivering mycophenolic acid (MPA), designed to improve MPA-related upper gastrointestinal adverse events by delaying the release of MPA until the small intestine. A r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98cc2907725777af6398127911e38086
https://pubmed.ncbi.nlm.nih.gov/16008604
https://pubmed.ncbi.nlm.nih.gov/16008604